Overcoming Regulatory Hurdles in AAV Production, Upcoming Webinar Hosted by Xtalks

In this free webinar, understand the regulatory landscape and quality expectations for viral vector manufacturing in CGT. Attendees will learn why residual reagent clearance is critical for FDA compliance. The featured speakers will share solutions for AAV workflows and how to overcome associated regulatory challenges. Attendees will see how assay services can simplify regulatory submissions.

TORONTO, Oct. 7, 2025 /PRNewswire/ — As cell and gene therapy (CGT) advances, regulatory expectations around product quality and manufacturing rigor continue to rise, especially in viral vector production, such as AAV production. One emerging challenge is the need to demonstrate clearance of residual reagents used during upstream processing, a requirement increasingly emphasized by regulatory agencies like the FDA.

In this webinar, the featured speakers will explore how AAV manufacturers can address this pain point through strategic partnerships and innovations. They’ll introduce a newly developed residual reagent assay designed for use in AAV production workflows. This type of assay helps streamline regulatory submissions and supports quality assurance in viral vector workflows.

Register for this webinar to learn how this assay can support a compliance strategy and hear directly from the experts driving these innovations in AAV production.

Join Mike Molloy, Technical Director, BA Sciences; and Miguel Dominguez, Global Director, Field Applications and Support, Mirus Bio, for the live webinar on Wednesday, October 22, 2025, at 1pm EDT (10am PDT).

For more information or to register for this event, visit Overcoming Regulatory Hurdles in AAV Production.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit www.xtalks.com

For information about hosting a webinar, visit www.xtalks.com/why-host-a-webinar/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/overcoming-regulatory-hurdles-in-aav-production-upcoming-webinar-hosted-by-xtalks-302576606.html

SOURCE Xtalks

Staff

Recent Posts

Lightera Advances Fiber-integrated Temperature Feedback for Safer Laser-based Medical Procedures

SAN FRANCISCO, Jan. 16, 2026 /PRNewswire/ -- BiOS - Hall D Booth #8430, Photonics West Hall…

15 hours ago

DiagnosTear Announces Interim Clinical Results Indicating High Efficiency from TeaRx(TM) Red Eye

Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE:…

20 hours ago

NuGen Medical Devices Provides 2025 Year End Update on R&D and Strategic Progress

Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"…

21 hours ago

University of Phoenix and LinkedIn to host webinar on AI in nursing with skills and strategies for a new era of healthcare

January 22 virtual event "AI in Action: Skills and Strategies for a New Era of…

21 hours ago

Instinct Science Acquires ScribbleVet to Deliver the Next Generation of Intelligent-Native Veterinary Practice Management Software

The combination redefines PIMS by embedding AI, workflow, and clinical intelligence into a single system…

21 hours ago

Hemostemix Receives FDA Support for Its Basket Protocol Approach

Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE:…

1 day ago